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Cholangiocarcinoma is an intractable cancer, with no effective therapy other than surgical resection. Elevated vascular endothelial
growth factor (VEGF) and epidermal growth factor receptor (EGFR) expressions are associated with the progression of
cholangiocarcinoma. We therefore examined whether inhibition of VEGFR and EGFR could be a potential therapeutic target for
cholangiocarcinoma. Vandetanib (ZD6474, ZACTIMA), a VEGFR-2/EGFR inhibitor, was evaluated. Four human cholangiocarcinoma
cell lines were molecularly characterised and investigated for their response to vandetanib. In vitro, two cell lines (OZ and HuCCT1),
both of which harboured KRAS mutation, were refractory to vandetanib, one cell line (TGBC24TKB) was somewhat resistant,
and another cell line (TKKK) was sensitive. The most sensitive cell line (TKKK) had EGFR amplification. Vandetanib significantly
inhibited the growth of TKKK xenografts at doses X12.5mgkg
 1day
 1 (Po0.05), but higher doses (50mgkg
 1day
 1, Po0.05) of
vandetanib were required to inhibit the growth of OZ xenografts. Vandetanib (25mgkg
 1day
 1) also significantly (P¼0.006)
prolonged the time to metastasis in an intravenous model of TKKK metastasis. Inhibiting both VEGFR and EGFR signalling appears a
promising therapeutic approach for cholangiocarcinoma. The absence of KRAS mutation and the presence of EGFR amplification may
be potential predictive molecular marker of sensitivity to EGFR-targeted therapy in cholangiocarcinoma.
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Cholangiocarcinoma (cancer of the bile duct epithelium) is one of
the intractable cancers, whose incidence and mortality rates,
especially those of intrahepatic cholangiocarcinoma (IHCC), are
increasing worldwide (Khan et al, 2005). As cholangiocarcinoma is
difficult to diagnose at an early stage and no effective therapy other
than complete resection has been established, its prognosis is very
poor (5-year survival is 0–40% even in resected cases) (Khan et al,
2005; Sirica, 2005). Although gemcitabine-based chemotherapy
regimens have shown some potential in the treatment of
cholangiocarcinoma in recent years (Knox et al, 2005), novel
therapeutic strategies are required.
Recently, molecular-targeted therapies have become available
and have shown clinical benefit in some cancers (Gonzalez Angulo
et al, 2006; Tabernero, 2007). Epidermal growth factor receptor
(EGFR) and vascular endothelial growth factor receptor (VEGFR)
have emerged as potential therapeutic targets in cholangiocarci-
noma. Several studies have shown overexpression of EGFR,
amplification and mutation of EGFR genes (Gwak et al, 2005;
Nakazawa et al, 2005; Leone et al, 2006), and overexpression of
VEGF protein (Tang et al, 2006) in cholangiocarcinoma. A phase II
study of erlotinib, an EGFR kinase inhibitor, for advanced
cholangiocarcinoma suggests the clinical benefit for EGFR
inhibition in patients with cholangiocarcinoma (Philip et al, 2006).
The EGFR signalling pathway is associated with the progression,
proliferation, migration, and survival of cancer cells (Yarden and
Sliwkowski, 2001), and VEGF plays a key role in tumour-associated
neo-angiogenesis, which provides a tumour with oxygen, nutrition,
and a route for metastasis (Tabernero, 2007). In addition, VEGF
upregulation in tumour cells is considered to be a mechanism of
resistance to EGFR inhibitors (Viloria Petit et al, 2001). Earlier, we
have also reported that EGFR and VEGF overexpressions are
frequent in cholangiocarcinoma (B20 and 50%, respectively),
that EGFR overexpression is an independent prognostic factor in
IHCC, and that VEGF expression is associated with intrahepatic
metastasis in IHCC (Yoshikawa et al, 2008). These observations
prompted us to hypothesise that dual inhibition of both EGFR and
VEGFR may exert a synergistic anti-tumour effect in cholangio-
carcinoma.
In vivo imaging using bioluminescence can monitor tumour
growth in animals, providing longitudinal and temporal informa-
tion. Its value in the assessment of anti-cancer agents in vivo has
been recently confirmed in some animal models of cancer (Jenkins
et al, 2003; Nogawa et al, 2005). In this study, we established
bioluminescent cholangiocarcinoma cells and mouse xenograft
models of cholangiocarcinoma, and used these to assess the
activity of vandetanib (ZD6474, ZACTIMA), a VEGFR-2 and an
EGFR tyrosine kinase inhibitor, using an in vivo imaging system.
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sMATERIALS AND METHODS
Cholangiocarcinoma cell lines
Four human cholangiocarcinoma cell lines derived from Japanese
patients (TKKK, OZ, TGBC24TKB, and HuCCT1) were purchased
from RIKEN Bio Resource Center (Tsukuba, Japan, http://
www.brc.riken.jp/lab/cell/) or from the Japanese Collection of
Research Bioresources (Osaka, Japan, http://cellbank.nibio.go.jp/).
The TKKK cell line was derived from IHCC, and the OZ,
TGBC24TKB, and HuCCT1 cell lines from extrahepatic cholangio-
carcinoma.
Subcutaneous xenograft model
All animal experiment protocols were approved by the Committee
for Ethics in Animal Experimentation, and the experiments were
conducted in accordance with the Guideline for Animal Experi-
ments of the National Cancer Center (Tokyo, Japan).
Eight-week-old female BALB/c-nu/nu athymic mice were
purchased from Japan SLC (Hamamatsu, Japan). A total of
8 10
6 cells were suspended in 0.2ml of culture medium without
foetal bovine serum and injected subcutaneously into the right
flank of the mice. Tumour volume was calculated using the
following formula: (short diameter)
2 (long diameter)/2.
RT–PCR analysis for EGFR, VEGF, and VEGFR-2
Total RNA and genomic DNA were extracted from the four cell
lines. Total RNA of 1mg was converted into cDNA using a
Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel,
Switzerland) in accordance with the manufacturer’s instructions.
mRNA expression of EGFR, VEGF, and VEGFR-2 was assessed by
the RT–PCR method. Quantitative real-time PCR was conducted
using LightCycler480 (Roche) in accordance with the manufac-
turer’s instructions. TaqMan Probes (Applied Biosystems, Foster
City, CA, USA) for EGFR and VEGF were used. For standardisation
of the amount of RNA, expression of glyceraldehyde-3-phosphate
dehydrogenase in each sample was quantified. Primers are shown
in the Supplementary Table 1.
Mutation analysis of the EGFR and KRAS genes
For the sequence analysis of EGFR and KRAS, cDNA or genomic
DNA was sequenced after PCR amplification. Direct sequencing
was conducted using a BigDye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems) and analysed on an ABI Prism 3100
Sequencer (Applied Biosystems). Primers are shown in the
Supplementary Table 1.
Immunohistochemistry
Tissue preparation and immunohistochemistry (IHC) were con-
ducted as reported earlier (Yoshikawa et al, 2008). A polymer-
based method (EnvisionþDual Link System-HRP; Dako, Glostrup,
Denmark) was used for EGFR, VEGF, and Ki67 staining, and a
standard ABC method (Vectastain Elite ABC kit; Vector Labora-
tories, Burlingame, CA, USA) was used for CD34 staining. Sources
and dilutions of primary antibodies were as follows: mouse anti-
human EGFR (1:100 dilution, clone 31G7; Zymed, South San
Francisco, CA, USA), rabbit anti-human VEGF (1:50 dilution;
Zymed), mouse anti-human Ki67 (1:100 dilution, clone Ki-S5;
Chemicon, Temecula, CA, USA), and rat anti-mouse CD34 (1:50
dilution, clone MEC14.7; Abcam, Cambridge, UK).
Terminal deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate-biotin nick end labelling (TUNEL) was conducted to
assess the degree of apoptosis by using an In Situ Cell Death
Detection Kit, POD (Roche) in accordance with the manufacturer’s
instructions.
Fluorescence in situ hybridisation for the EGFR gene locus
EGFR gene copy number per cell was investigated by fluorescence
in situ hybridisation (FISH) using the LSI EGFR SpectrumOrange/
CEP7 SpectrumGreen probe (Vysis, Downers Grove, IL, USA), in
accordance with a published protocol (Ooi et al, 2004). Positivity
for gene amplification was defined as the presence of clustered
signals or X4 copies of orange signals.
Drug and formulation
Vandetanib was provided by AstraZeneca (Macclesfield, UK). For
the in vitro study, vandetanib was formulated as a 10-mM stock in
100% dimethylsulphoxide and stored at  201C. Just before in vitro
use, the stock solution was diluted in culture medium to the
required concentration. For the in vivo study, vandetanib was
administered as a homogeneous suspension with 1% polysorbate
(Tween 80; MP Biomedicals, Solon, OH, USA) and administered
orally once a day at 0.1ml/10g body weight (b.w.).
Cell proliferation assay
Cell sensitivity to vandetanib was estimated using the 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulpho-
phenyl)-2H-tetrazolium, inner salt (MTS) assay. The CellTiter 96
AQueous One Solution Reagent (Promega, Madison, WI, USA) was
used in accordance with manufacturer’s instructions. A total of
5000 cells suspended in 100ml of 10% foetal bovine serum-
containing culture medium per well were placed on a 96-well
culture plate and treated with various concentrations of vandeta-
nib (0–100mM). After 72h, 20ml of the reagent was added, and
the absorbance at 490nm was recorded. The experiment was
conducted in triplicate and repeated three times. All data were
calculated as a ratio to control, which means a ratio of absorbance
in each concentration of vandetanib treatment relative to that in
the negative control, and presented as mean±s.d.
Western blot analysis investigating molecular effects of
vandetanib in vitro
Each cell starved for 24h was exposed to various concentrations of
vandetanib for 2h, and stimulated by human EGF (1ngml
 1,
Wakunaga Pharmaceutical Co., Osaka, Japan) for 10min. Cell
pellets were dissolved in lysis buffer (1% Triton X-100; 10mM Tris-
HCl, pH 7.5; 150mM NaCl) with a protease inhibitor cocktail
(Roche) and a phosphatase inhibitor cocktail (Nacarai Tesque,
Kyoto, Japan). Equal amounts (16mg) of cell extracts were
electrophoresed, transferred to polyvinylidene difluoride mem-
brane (Millipore, Billerica, MA, USA), and immunoblotted with the
following antibodies: mouse anti-EGFR antibody (clone 13/EGFR,
BD Bioscience, Franklin Lakes, NJ, USA), mouse anti-phosphory-
lated EGFR (pEGFR, Tyr 1068, clone 1H12; Cell Signaling
Technology, Beverly, MA, USA), mouse anti-AKT (clone 2H10,
Cell Signaling Technology), mouse anti-phosphorylated AKT
(pAKT, Ser473, clone 587F11; Cell Signaling Technology), rabbit
anti-MAPK (mitogen-activated protein kinase; Cell Signaling
Technology), mouse anti-phosphorylated MAPK (Thr202/Tyr204,
clone E10; Cell Signaling Technology), rabbit anti-VEGF (Lab
Vision, Fremont, CA, USA), and mouse anti-b-actin (clone AC-15,
Sigma, St Louis, MO, USA). All antibodies were diluted to use in
accordance with the manufacturer’s instructions.
Reporter gene labelling of tumour cells
TKKK and OZ cells were transfected with a complex of 4mg
pEGFP-Luc plasmid DNA (Minakuchi et al, 2004) and 10ml
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA)
in accordance with the manufacturer’s instructions. Stable
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 1 geneticin (Invitrogen).
Clones strongly expressing the luciferase gene (named TKKK-Luc
and OZ-Luc) were selected and used in the in vivo study.
In vivo tumour imaging
For the in vivo tumour imaging, D-luciferin 150mg/kg per b.w.
(Promega) was administered to mice by intraperitoneal injection.
After 15min, photons from animal whole bodies were counted
using the IVIS imaging system (Xenogen, Alameda, CA, USA) in
accordance with the manufacturer’s instructions. Data were
analysed using the LIVINGIMAGE 2.50.1 software (Xenogen).
Effects of vandetanib in a xenograft model
The therapeutic and anti-metastatic activities of vandetanib were
estimated using a mouse xenograft model. According to the
therapeutic protocol, 8 10
6 of TKKK-Luc and OZ-Luc cells were
injected subcutaneously. When tumour volume exceeds 20mm
3,
the mice were randomly divided into four treatment groups,
namely vandetanib 50, 25, or 12.5mg/kg per b.w. per day, or
vehicle control. Treatment started from the next day and
continued for at least 4 weeks. Photons from animal whole bodies
were counted twice a week. All mice were killed at the end of the
study period and subcutaneous tumours were removed completely.
After the tumour volume was calculated, tumours were cut
through the maximum diameter. Half of them were fixed in 10%
formalin, and paraffin-embedded, and haematoxylin–eosin
staining, IHC for CD34 (microvessel marker) and Ki67
(proliferation marker), and TUNEL (apoptosis marker) were
conducted to investigate histological effects of vandetanib.
Haematoxylin–eosin sections were observed microscopically and
whole-scanned using a film scanner (Cool Scan; Nikon, Tokyo,
Japan). The total tumour area and the necrotic tumour area
through the maximum diameter were calculated using Image J
software (NIH, http://rsb.info.nih.gov/ij/), and the percentage of
the necrotic area was calculated. Evaluation of IHC for CD34 and
Ki67 and for TUNEL was conducted by DY and two pathologists
(HO and TS), using standard light microscopy without
knowledge of any therapeutic intervention. Microvessel density
(MVD) was defined as the mean number of microvessels in three
fields (original magnification,  200) containing high levels of
CD34-stained microvessels (‘hotspots’). Ki67 proliferation index
(PI) and apoptotic index (AI) were defined as the percentage of
positive cells among 1000 tumour cells or over at the hotspot.
The others were immediately frozen in liquid nitrogen and
dissolved in lysis buffer with protease and phosphatase inhibitors
to investigate molecular effects of vandetanib, and the expression
of EGFR, pEGFR, and VEGFR-2 in both treatment (vandetanib
50mg/kg per b.w. per day) and vehicle control groups were
assessed by using western blot analysis. Rabbit anti-VEGFR-2
antibody (Lab Vision) was used in accordance with the
manufacturer’s instructions.
To evaluate the effects on tumour metastasis, an intravenous
tumour cell-seeding model was used (anti-metastatic protocol).
TKKK-Luc cells (4 10
6) were suspended in 200ml of PBS and
were injected into mice through the tail vein after 7 days of daily
administration of vandetanib 25mg/kg per b.w. per day or vehicle
control. Mice were then treated 5 days a week for 3 months, and
photon counting was conducted once a week. If the photon signal
was visualised on the IVIS imaging system, the mouse was
considered as having a metastasis. The time to metastasis was
estimated as an index of the anti-metastatic effect of vandetanib.
At the end of the study, all mice were killed and autopsied. All
organs, including the lung and brain, were formalin-fixed and
sliced at 3-mm intervals, and the presence of tumours was
confirmed microscopically.
Correlations between expression and gene amplification of
EGFR in clinical samples
Epidermal growth factor receptor expression was assessed by IHC
in samples from 90 cases of cholangiocarcinoma that had been
resected at the National Cancer Center Hospital. Among these
samples, EGFR gene amplification was also examined in 19 EGFR-
positive and 15 EGFR-negative samples, and the correlation
between protein expression and gene amplification of EGFR was
investigated. This study was approved by the Ethics Committee of
the National Cancer Center (Tokyo, Japan), and written informed
consent was obtained from all patients.
Statistics
All statistical analyses were performed with the Statview 5.0
statistical software package (Abacus Concepts, Berkeley, CA, USA).
For the therapeutic protocol, change of photon count was
estimated using repeated measures analysis of variance (ANOVA)
followed by Dunnett’s post hoc test. Between-group comparisons of
response to vandetanib (tumour volume, necrotic area, MVD, PI,
and AI) were estimated using one-way ANOVA followed by
Dunnett’s post hoc test. For the anti-metastatic protocol, the time
to metastasis curve was calculated using the Kaplan–Meier
method, and log-rank test was performed for the comparison of
the time to metastasis curves. Correlations between treatment and
occurrence of metastasis in the anti-metastatic protocol, and
between expression and gene amplification of EGFR in the clinical
samples were assessed using Fisher’s exact probability test. All
numerical data were presented as mean±s.d. Differences at
Po0.05 were considered as statistically significant.
RESULTS
Molecular characteristics of four cholangiocarcinoma cell
lines
Epidermal growth factor receptor and VEGF mRNA were detected
in all four cholangiocarcinoma cell lines (Figure 1A), but VEGFR-2
mRNA was not expressed in any of them (Figure 1B). As none of
these cell lines expressed VEGFR-2, we assume that the direct
effect of vandetanib against these cells was mainly mediated by its
anti-EGFR effect. Among the four cell lines, TKKK cells showed
the highest expression of both EGFR and VEGF (Figure 1A).
Epidermal growth factor receptor and VEGF proteins were also
detected in all cell lines, and EGFR protein expression levels were
correlated with mRNA levels, but VEGF were not (Figures 1A
and C). The expression levels of VEGF mRNA may not always
correspond with those of VEGF protein, as VEGF mRNA is labile
under the normal oxygen tension and some translational regula-
tion of VEGF expression has been reported (Levy et al, 1996;
Mezquita et al, 2005). Epidermal growth factor receptor and VEGF
protein expressions were also confirmed by IHC in xenograft
tumours (Figure 1D). Fluorescence in situ hybridisation analysis
revealed EGFR gene amplification only in TKKK cells (Figure 1E).
We also sequenced the kinase domain of EGFR gene, but found no
EGFR mutation in any of the cell lines. KRAS mutation was
detected in OZ (Q61L) and HuCCT1 (G12D) cell lines, but not in
TKKK and TGBC24TKB cell lines.
Anti-proliferative effect of vandetanib in vitro
The effect of vandetanib on proliferation in each cell line is shown
in Figure 2A. The vandetanib IC50 for the PC-9 lung cancer cell
line, which is sensitive to EGFR inhibitors, was reported earlier to
be 0.14mM (Taguchi et al, 2004). Compared with this data, TKKK
cells were also sensitive to vandetanib (IC50: 0.22mM), TGBC24TKB
was moderately resistant (IC50: 4.5mM), and OZ and HuCCT1 cells
VEGFR/EGFR inhibitor in cholangiocarcinoma
D Yoshikawa et al
1259
British Journal of Cancer (2009) 100(8), 1257–1266 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s(IC50s of 12.2 and 10mM, respectively) were considered refractory.
Next, we examined the expression of VEGF and EGFR, and also the
phosphorylation status of downstream molecules (AKT and
MAPK) of EGFR in four cell lines (Figure 2B). No significant
change in VEGF, EGFR, AKT, pAKT, or MAPK expression was
observed after vandetanib treatment. Phosphorylation of EGFR
was inhibited by vandetanib treatment in all cell lines, and it can
be noted that phosphorylation of MAPK was inhibited in TKKK
and TGBC24TKB (not refractory to vandetanib) cell lines but not
in OZ and HuCCT1 (refractory to vandetanib) cell lines.
Anti-tumour effects of vandetanib in vivo
The in vivo anti-tumour effect of vandetanib against an in vitro-
sensitive cell line (TKKK-Luc derived from TKKK) and an in vitro
refractory cell line (OZ-Luc derived from OZ) was then evaluated
using subcutaneous xenografts. The tumour growth curves
analysed by the IVIS imaging system are shown in Figures 3A
and B. As expected from the in vitro study, growth of the TKKK-
Luc xenograft was significantly suppressed by vandetanib treat-
ment at a lower dose, 12.5–25mgkg
 1, whereas reduction of the
OZ-Luc xenograft tumour was observed at a vandetanib dose of
50mgkg
 1. At the end of the study, tumour volume was
significantly lower in the vandetanib 50mgkg
 1 group of the
OZ-Luc xenograft and in the 12.5–50mgkg
 1 group of the
TKKK-Luc xenograft than in the vehicle-treated control
group (Figure 4A). Histologically, OZ-Luc tumours treated with
vandetanib showed substantial necrosis, the necrotic area being
significantly greater than for the vehicle-treated control group
(Figures 4B and C, black allows). TKKK-Luc tumours did not show
any substantial necrotic area in either the vandetanib-treated or
the vehicle-treated groups (data not shown), but tumour glands
including degenerate tissues were increased (Figure 4C, blue
arrows). Feature of cytological degeneration such as clear
cytoplasmic change were frequent in the vandetanib-treated TKKK
and OZ xenografts compared with the vehicle-treated tumours
(Figure 4C). Microvessel density (Figure 5A) and PI (Figure 5B)
were significantly decreased in all vandetanib-treated groups of
both the OZ-Luc and TKKK-Luc xenografts. AI (Figure 5C) was
significantly increased in the vandetanib 50mgkg
 1 group of the
OZ-Luc xenograft, and in the vandetanib 25 and 50mgkg
 1 groups
of TKKK-Luc xenograft. In both xenografts, EGFR, pEGFR, and
VEGFR-2 expression were reduced by vandetanib treatment
(Figures 6A and B). According to the molecular characters of
these cells, VEGFR-2 is supposed to be expressed in the tumour
stroma, but not in tumour cells.
Box plots in Figures 4 and 5 present that upper and under bar
means 90th and 10th percentile, box means between 25th and 75th
percentile, and the line in the box means median. Representative
expression of CD34, Ki67, and TUNEL is shown in Supplementary
Figure 1, and mean values of histological assessment data are
shown in Supplementary Table 2.
Anti-metastatic effects of vandetanib in vivo
We next assessed whether vandetanib treatment might have effects
on the establishment and growth of distant metastasis using an
intravenous tumour cell-seeding model. Preliminary evaluations
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Figure 1 Characteristics of the four cholangiocarcinoma cells. (A) Epidermal growth factor receptor (EGFR) and VEGF mRNA expressions (by real-time
PCR). (B) Vascular endothelial growth factor receptor-2 mRNA expression (VEGFR-2, by RT–PCR; lane 1, human liver tissue; lane 2, TKKK; lane 3, OZ;
lane 4, TGBC24TKB; lane 5, HuCCT1; and lane 6, no RNA). The arrow indicates the band of VEGFR-2. (C) Epidermal growth factor receptor and VEGF
expressions (by western blotting; lane 1, TKKK; lane 2, OZ; lane 3, TGBC24TKB; and lane 4, HuCCT1). (D) Epidermal growth factor receptor and VEGF
expressions in vivo (by immunohistochemistry). Scale bar¼0.1mm. Epidermal growth factor receptor and VEGF were expressed in all cells, but VEGFR-2
was not. (E) Fluorescence in situ hybridization for the EGFR locus in TKKK (orange, EGFR; green, centrosome7).
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sconfirmed the presence of lung metastases within 3 months in two
of three (67%) mice inoculated with TKKK-Luc cells from the tail
vein. Next, 18 mice per group (vandetanib 25mgkg
 1 or vehicle
treatment) were challenged with intravenous tumour cell inocula-
tion, and time to metastasis was assessed using the IVIS imaging
system. No mice died throughout the 3-month observation period.
The time to metastasis was significantly prolonged in the
vandetanib group compared with the vehicle-treated group
(median: 84 vs 63 days, P¼0.006, Figure 3C). At the end of the
study, metastases were present in 15 out of 18 (83.3%) of the
control group and 9 out of 18 (50.0%) of the vandetanib group
(P¼0.075). Lung and brain metastases were found in 20 and 6
mice, respectively. Most tumours were histologically identified as
micronodules or assembled tumour cells (Figure 3C).
Correlations between expression and gene amplification of
EGFR in clinical samples
Out of 90 cholangiocarcinoma samples, 19 (21.1%) were tested
EGFR-positive by IHC. Among these cases, EGFR gene amplifica-
tion was examined by FISH in the 19 EGFR-positive and 15
EGFR-negative samples. Of these 34 samples 8 had EGFR gene
amplification, of which all 8 were confirmed as EGFR-positive by
IHC. In contrast, none of the EGFR-negative samples were found
to have gene amplification (P¼0.0045).
DISCUSSION
Vandetanib is a tyrosine kinase inhibitor of both VEGFR-2 and
EGFR, and preclinical studies have confirmed its anti-tumour
effects in a range of cancer types (Wedge et al, 2002; Ciardiello
et al, 2004; Taguchi et al, 2004; Williams et al, 2004; Yano et al,
2005). Phase III clinical studies are now underway with vandetanib
in non-small-cell lung cancer following promising results in phase
I and II studies (Holden et al, 2005; Natale et al, 2006; Tamura
et al, 2006; Heymach et al, 2007a,b). We have reported earlier that
both EGFR and VEGF overexpressions are associated with
progression of cholangiocarcinoma (Yoshikawa et al, 2008), and
hypothesised that simultaneously blocking the EGFR and VEGF
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Figure 2 (A) The anti-proliferative effect of vandetanib against cholangiocarcinoma cell lines (TKKK, OZ, TGBC24TKB, and HuCCT1) in vitro. All data are
presented as mean±s.d. A ratio to control means a ratio of absorbance in each concentration of vandetanib treatment relative to that in the negative
control. (B) The western blot analysis of VEGF, EGFR, and phosphorylation of markers downstream of EGFR. Vandetanib inhibited phosphorylation of EGFR
in all cell lines, but phosphorylation of MAPK was inhibited only in TKKK and TGBC24TKB cell lines.
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spathways might have synergistic therapeutic effects against
cholangiocarcinoma. In this study, we investigated the efficacy of
vandetanib in cholangiocarcinoma cell lines and in xenograft
models, and report here that vandetanib strongly inhibits tumour
progression in vivo.
Anti-proliferative effects of vandetanib in vitro
As VEGFR-2 was not expressed in any of cholangiocarcinoma cell
lines, we assumed that the anti-proliferative effects of vandetanib
observed in this in vitro study were mainly because of the
inhibition of EGFR signalling. All cholangiocarcinoma cell lines
examined in this study expressed EGFR and VEGF, but the degree
of the anti-proliferative effect of vandetanib in vitro varied
between the cell lines. TKKK cells were sensitive to vandetanib,
TGBC24TKB cells were moderately resistant to vandetanib,
whereas OZ and HuCCT1 cells were refractory to vandetanib. This
finding is partly consistent with an earlier report that HuCCT1 cell
line was resistant to the EGFR inhibitor, erlotinib (Jimeno et al,
2005). It is interesting that KRAS mutations were found in both cell
lines (HuCCT1 and OZ) considered refractory to vandetanib in this
study, and KRAS mutation has been reported as a mechanism of
resistance to EGFR inhibitors in lung and colorectal cancers (Pao
et al, 2005; Lievre et al, 2006). Vandetanib strongly suppressed
EGFR phosphorylation in this study, but phosphory-
lation of downstream MAPK was not inhibited in the OZ and
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cholangiocarcinoma cells, upregulation of the RAS/RAF/MAPK
pathway by mutant KRAS might counteract the anti-growth effect
of vandetanib by EGFR inhibition. The incidence of KRAS
mutation in cholangiocarcinoma is estimated to be 54–67%
(Tada et al, 1990; Tannapfel et al, 2000), and therefore it may be
important to examine the KRAS status when evaluating the activity
of EGFR inhibitors in cholangiocarcinoma.
In non-small-cell lung cancer, EGFR mutation and/or amplifica-
tion have been reported as possible predictive factors of sensitivity
to EGFR tyrosine kinase inhibitors (Lynch et al, 2004; Paez et al,
2004; Pao et al, 2004; Cappuzzo et al, 2005). Of the cell lines
without KRAS mutation, TKKK, which has EGFR amplification,
was most sensitive to vandetanib. The incidence of EGFR
mutations in cholangiocarcinoma is reported as 13.6–15.0%
(Gwak et al, 2005; Leone et al, 2006). However, we did not detect
mutation in the kinase domain of the EGFR gene in the cell lines
used in this study. We have reported earlier that EGFR over-
expression occurs in B20% of primary cholangiocarcinomas and
is associated with tumour progression and poor outcome
(Yoshikawa et al, 2008). In this study, our FISH analysis of
clinical samples revealed that EGFR gene amplification was present
in 42% (8 out of 19) of samples with EGFR overexpression, but
absent in samples lacking EGFR overexpression. This result is
consistent with an earlier report that EGFR amplification was
found in 6.8% of cholangiocarcinomas (Nakazawa et al, 2005).
Collectively, the EGFR and KRAS gene status may be a potential
biomarker for predicting the response to inhibitors of EGFR
including vandetanib in cholangiocarcinoma.
Anti-tumour effects of vandetanib in vivo
On the basis of the in vitro data, we tested TKKK (the most
sensitive) and OZ (the most resistant) cells in an in vivo
therapeutic model. As VEGFR-2 was not expressed in both cells,
direct anti-tumour effect of vandetanib in this study was anti-
EGFR inhibition, and anti-VEGFR-2 inhibition of vandetanib was
exerted in the tumour stroma. Vandetanib greatly suppressed the
tumour growth of the TKKK xenograft through anti-EGFR and
VEGFR-2 inhibition, consistent with the in vitro study. However,
vandetanib also inhibited tumour growth even in the OZ
(refractory to EGFR inhibition) xenograft, when given at higher
dose. Vascular endothelial growth factor receptor-2 expression in
OZ xenograft with high-dose vandetanib treatment was also
reduced, and histologically, both TKKK and OZ tumours treated
with vandetanib showed necrosis, reduced microvessels, reduced
proliferation, and increased apoptosis. Therefore, the anti-tumour
effect of vandetanib in this model appears to be mediated by
inhibiting tumour angiogenesis (anti-VEGFR effect) as well as by
directly inhibiting tumour cell proliferation (anti-EGFR effect).
However, at lower doses of vandetanib, growth of OZ (refractory to
the anti-proliferative effects of EGFR inhibition) xenograft was not
significantly inhibited despite the proliferation and angiogenesis
being reduced. These in vivo experiments suggest that anti-EGFR
treatment is effective in cholangiocarcinoma with activated EGFR
signalling (e.g., EGFR amplification), and that inhibiting stromal
angiogenesis through VEGFR inhibition also contributes to
abrogate tumour environment and suppress tumour growth,
although the synergistic effect between EGFR and VEGFR-2
inhibition was not clear in this study. As cholangiocarcinoma
cases expressing VEGFR-2 was reported (Wiedmann et al, 2006),
VEGFR-2 inhibition may also be directly effective in a part of
cholangiocarcinoma. Collectively, targeting both angiogenesis and
the active growth signal pathway, for example, inhibiting EGFR,
might exert an auxiliary effect, leading to robust tumour regression
in cholangiocarcinoma.
Anti-metastatic effects of vandetanib in vivo
Metastasis is a main cause of cancer death, and intrahepatic or
lymph node metastases are independent prognostic factors in
cholangiocarcinoma (Yoshikawa et al, 2008). An in vivo imaging
system was used in the intravenous tumour cell-seeding study to
elucidate whether vandetanib has an anti-metastatic effect. As
in vivo tumour imaging can observe chronological changes in
tumour growth in the individual animals with a high degree of
sensitivity, which has been difficult to estimate by other current
methods (Jenkins et al, 2003), time to metastasis was assessed as
an index of anti-metastatic effects in our model. The time to
metastasis in the vandetanib-treated group was significantly longer
than that in the vehicle-treated group, although the final incidence
of metastasis was not statistically different between the two groups
at the end of study.
Decreasing activity of MAPK, which is a downstream molecule
of the EGFR pathway, reduces tumour proliferation in vivo
(Aguirre Ghiso et al, 2003). In animal models, an EGFR inhibitor,
gefitinib, prevents carcinogenesis of gallbladder and lung cancer
(Kiguchi et al, 2005; Yan et al, 2006), and reduces the incidence of
metastasis of prostate carcinoma cells (Angelucci et al, 2006). In
our model, EGFR inhibition contributed to the anti-metastatic
effect of vandetanib. Moreover, angiogenesis is essential for the
growth of tumours more than 1–2mm in diameter (Fidler and
Ellis, 1994; Ellis and Fidler, 1996; Yano et al, 2005), and VEGF is
necessary for the formation of metastatic tissues at the primary site
(Ku ¨sters et al, 2007). It is possible that VEGFR inhibition at the
primary site may reduce the hematogenic metastasis in cholan-
giocarcinoma. Indeed, VEGF expression is associated with
intrahepatic metastasis in IHCC (Yoshikawa et al, 2008). Although
the underlying molecular mechanism remains to be clarified, our
results indicate that vandetanib may have potential as a post-
operative adjuvant therapy to inhibit the establishment and growth
of metastases in cholangiocarcinoma.
Conclusion
In summary, our preclinical study revealed that dual blockade of
VEGFR and EGFR signalling by vandetanib resulted in considerable
therapeutic effects in a mouse model of cholangiocarcinoma. Our
results also suggest that vandetanib may have potential as a
A
B
OZ xenograft Vandetanib 50 mg kg–1 Vehicle control
EGFR
pEGFR (Tyr1068)
VEGFR-2
CBB
TKKK xenograft Vandetanib 50 mg kg–1 Vehicle control
EGFR
pEGFR (Tyr1068)
VEGFR-2
CBB
Figure 6 The western blot analysis of EGFR, pEGFR, and VEGFR-2
expressions after vandetanib (50mg/kg per b.w.) and vehicle treatment in
the therapeutic protocol. (A) OZ-Luc xenografts and (B) TKKK-Luc
xenografts. CBB, Coomassie Brilliant Blue staining.
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spostoperative adjuvant therapy in these tumours. Moreover, both the
absence of KRAS mutation and the presence of EGFR amplification
appear promising biomarkers for predicting the response of
cholangiocarcinoma to agents that inhibit EGFR (such as vandetanib).
As no standard chemotherapy for cholangiocarcinoma has been
established to date, further investigation at the clinical setting,
including biomarker evaluation, is urgently required.
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